



foi.request@mhra.gov.uk.

[MHRA Website](#)

Our Ref: **FOI2026/00377**

06 May 2026

Dear [REDACTED]

Thank you for your Freedom of Information (Fol) request received on 7 April. You wrote:

I would like to request for Module 2.4, Module 2.5, Module 2.6 and Module 2.7 submitted for Melatonin 1 mg/ml oral solution, MAH: Glenmark Pharmaceuticals Europe Ltd, (PL 25258/0402).

MHRA Response

The Agency has completed its search for the information you have requested and we are able to confirm that we do hold some of the information that you have requested.

In response to your request, please find attached the Clinical Overview and Non-Clinical Overview for Melatonin 1 mg/ml oral solution from Glenmark Pharmaceuticals Europe Ltd (PL 25258/0402).

Following a search of our electronic records, we have established that Module 2.6 and Module 2.7 are not held by this Agency.

Please note that the documentation provided has been redacted under Section 40 (Personal information), Section 41 (Information given in confidence) and Section 43 (Commercial interests) of the Freedom of Information Act.

Disclosure of information subject to Section 40 (Personal information) would be an infringement of personal data. Section 40 (Personal information) is an absolute exemption, and no consideration of the public interest is required.

Section 41 (Information given in confidence) is an absolute exemption, and no consideration of the public interest is necessary, except to state that the release of this information withheld under this section of the FOI Act would be considered an actionable breach by the MHRA.

We have redacted some parts of the attached documentation under Section 43 (Commercial interests) of the FOI Act because the release of all, or part of, the information would, or would be likely to, cause harm to the third party's commercial interests. The exemption is to safeguard the commercially sensitive information/commercial enterprise. In this case, release of information would enable the competitors to overcome several regulatory hurdles in the research and development of their own products. This exemption is conditional on the public

interest in releasing it not outweighing the company's/commercial enterprise's right to confidentiality and the probable damage that the company/commercial enterprise could suffer as a result of the information being released. We have considered the balance of the public interest when applying this exemption. In this case, we have not identified any issues which would benefit the public, as a whole, by being brought to their attention.

If you have any queries about this letter, please contact us quoting the reference number above.

Yours sincerely,

MHRA Central Freedom of Information Team
Medicines & Healthcare products Regulatory Agency

Your right to complain under the Freedom of Information Act

If you are not happy with this response you may request an internal review by e-mailing foi.request@mhra.gov.uk or by writing to: MHRA Central Freedom of Information Team, 10 South, Colonnade, Canary Wharf, London, E14 4PU

Any request for an internal review must be received by us within 40 working days of the date of this letter. Please note we are not obliged to provide a review if it is requested after more than 40 working days.

If you are not content with the outcome of the internal review you may apply directly to the Information Commissioner's Office for a decision. Generally, the Commissioner cannot make a decision unless you have exhausted our own complaints procedure. The Information Commissioner can be contacted at: The Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

Website: [ICO FOI and EIR complaints](#) or telephone 0303 123 1113.

Re-use of our information

The MHRA information supplied in response to your request is subject to Crown copyright. Information created by the MHRA which is disclosed under the Freedom of Information Act is made available for re-use under the Open Government Licence (OGL) v3.0, except where this is otherwise stated. There are some restrictions on re-use under the OGL and these can be viewed here:

<https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/>